Magrolimab plus azacitidine versus azacitidine plus placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study.
Garcia-Manero G., Daver NG., Xu J., Chao M., Chung T., Tan A., Wang V., Wei A., Vyas P., Sallman DA.